NO329918B1 - Farmasoytisk preparat, samt fremgangsmate til fremstilling derav - Google Patents

Farmasoytisk preparat, samt fremgangsmate til fremstilling derav Download PDF

Info

Publication number: NO329918B1
Authority: NO; Norway
Prior art keywords: dried; pharmaceutical preparation; independently represent; preparation according; drying
Prior art date: 1997-07-11

Application number

NO20000123A

Other languages

English (en)

Norwegian (no)

Other versions

NO20000123D0 (no

NO20000123L (no

Inventor

Joanne Broadhead

Original Assignee

Astrazeneca Uk Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-11

Filing date

2000-01-10

Publication date

2011-01-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO329918(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-01-10 Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd

2000-01-10 Publication of NO20000123D0 publication Critical patent/NO20000123D0/no

2000-03-03 Publication of NO20000123L publication Critical patent/NO20000123L/no

2011-01-24 Publication of NO329918B1 publication Critical patent/NO329918B1/no

Links

238000002360 preparation method Methods 0.000 title claims description 22
239000000825 pharmaceutical preparation Substances 0.000 title claims description 17
238000000034 method Methods 0.000 title claims description 10
150000001875 compounds Chemical class 0.000 claims description 17
150000003839 salts Chemical class 0.000 claims description 14
-1 NR<6>R<7> Chemical group 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 10
238000004108 freeze drying Methods 0.000 claims description 10
125000003729 nucleotide group Chemical group 0.000 claims description 10
229910052736 halogen Inorganic materials 0.000 claims description 9
150000002367 halogens Chemical class 0.000 claims description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
229930006000 Sucrose Natural products 0.000 claims description 6
230000002378 acidificating effect Effects 0.000 claims description 6
238000001035 drying Methods 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
239000005720 sucrose Substances 0.000 claims description 6
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 5
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 5
125000001424 substituent group Chemical group 0.000 claims description 5
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
229920002307 Dextran Polymers 0.000 claims description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
239000008101 lactose Substances 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
238000007887 coronary angioplasty Methods 0.000 claims description 3
239000000600 sorbitol Substances 0.000 claims description 3
238000011282 treatment Methods 0.000 claims description 3
208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
206010002383 Angina Pectoris Diseases 0.000 claims description 2
238000009472 formulation Methods 0.000 claims description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
238000001694 spray drying Methods 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
125000000185 sucrose group Chemical group 0.000 claims 1
239000003814 drug Substances 0.000 description 6
238000003860 storage Methods 0.000 description 5
230000001732 thrombotic effect Effects 0.000 description 5
239000002773 nucleotide Substances 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000007774 longterm Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000010118 platelet activation Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
206010002388 Angina unstable Diseases 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
206010047249 Venous thrombosis Diseases 0.000 description 2
KVLRBRZHCOVMNX-IDTAVKCVSA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(NCCSC)=NC(SCCC(F)(F)F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O KVLRBRZHCOVMNX-IDTAVKCVSA-N 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000002792 vascular Effects 0.000 description 2
XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
206010014498 Embolic stroke Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000014767 Myeloproliferative disease Diseases 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
229920000388 Polyphosphate Polymers 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
229910006069 SO3H Inorganic materials 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010040621 Shunt occlusion Diseases 0.000 description 1
208000005485 Thrombocytosis Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010043647 Thrombotic Stroke Diseases 0.000 description 1
201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
208000032109 Transient ischaemic attack Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
208000012346 Venoocclusive disease Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
206010003230 arteritis Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
150000007516 brønsted-lowry acids Chemical class 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
229940125890 compound Ia Drugs 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000007323 disproportionation reaction Methods 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000013171 endarterectomy Methods 0.000 description 1
238000002618 extracorporeal membrane oxygenation Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
238000007496 glass forming Methods 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
238000002616 plasmapheresis Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001205 polyphosphate Substances 0.000 description 1
235000011176 polyphosphates Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000002278 reconstructive surgery Methods 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
239000003352 sequestering agent Substances 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
239000003634 thrombocyte concentrate Substances 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
230000008733 trauma Effects 0.000 description 1
125000004417 unsaturated alkyl group Chemical group 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO20000123A 1997-07-11 2000-01-10 Farmasoytisk preparat, samt fremgangsmate til fremstilling derav NO329918B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9702680A SE9702680D0 (sv)	1997-07-11	1997-07-11	New formulation
PCT/SE1998/001287 WO1999002542A1 (en)	1997-07-11	1998-06-29	New formulation

Publications (3)

Publication Number	Publication Date
NO20000123D0 NO20000123D0 (no)	2000-01-10
NO20000123L NO20000123L (no)	2000-03-03
NO329918B1 true NO329918B1 (no)	2011-01-24

Family

ID=20407718

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20000123A NO329918B1 (no)	1997-07-11	2000-01-10	Farmasoytisk preparat, samt fremgangsmate til fremstilling derav

Country Status (35)

Country	Link
US (1)	US6130208A (cs)
EP (1)	EP1000079B1 (cs)
JP (1)	JP4950380B2 (cs)
KR (1)	KR100786654B1 (cs)
CN (2)	CN1263533A (cs)
AR (1)	AR013157A1 (cs)
AT (1)	ATE340801T1 (cs)
AU (1)	AU8362598A (cs)
BR (1)	BR9810703A (cs)
CA (1)	CA2295628C (cs)
CY (1)	CY1105805T1 (cs)
CZ (1)	CZ298110B6 (cs)
DE (1)	DE69836023T2 (cs)
DK (1)	DK1000079T3 (cs)
EE (1)	EE04119B1 (cs)
ES (1)	ES2273425T3 (cs)
HU (1)	HU226489B1 (cs)
ID (1)	ID24716A (cs)
IL (2)	IL133868A0 (cs)
IS (1)	IS2439B (cs)
MY (1)	MY116421A (cs)
NO (1)	NO329918B1 (cs)
NZ (1)	NZ502073A (cs)
PL (1)	PL192768B1 (cs)
PT (1)	PT1000079E (cs)
RU (1)	RU2216330C2 (cs)
SA (1)	SA98190328B1 (cs)
SE (1)	SE9702680D0 (cs)
SI (1)	SI1000079T1 (cs)
SK (1)	SK285766B6 (cs)
TR (1)	TR200000006T2 (cs)
TW (1)	TW585764B (cs)
UA (1)	UA65576C2 (cs)
WO (1)	WO1999002542A1 (cs)
ZA (1)	ZA985669B (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4986281B2 (ja) *	2004-10-05	2012-07-25	旭化成ファーマ株式会社	補酵素の安定化方法およびその組成物
US20130303477A1 (en)	2008-05-13	2013-11-14	The Medicines Company	Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en)	2008-05-13	2009-11-19	The Medicines Company	Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en)	2008-05-13	2012-06-07	Lisa Ruderman Chen	Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en)	2009-11-11	2016-08-30	The Medicines Company	Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en)	2008-05-13	2014-06-24	The Medicines Company	Maintenance of platelet inhibition during antiplatelet therapy
WO2011024933A1 (ja)	2009-08-28	2011-03-03	第一三共株式会社	３－（ビアリールオキシ）プロピオン酸誘導体
US10376532B2 (en)	2009-11-11	2019-08-13	Chiesi Farmaceutici, S.P.A.	Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt)	2009-11-11	2021-12-14	Chiesi Farmaceutici S.P.A.	Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
RU2606845C2 (ru) *	2010-12-10	2017-01-10	СИГМАФАРМ ЛЭБОРЭТОРИЗ, ЭлЭлСи	Высокостабильные композиции перорально активных аналогов нуклеотидов или перорально активных пролекарств аналогов нуклеотидов
WO2012109406A1 (en)	2011-02-09	2012-08-16	The Medicines Company	Methods for treating pulmonary hypertension
US9700347B2 (en)	2011-08-17	2017-07-11	Samuel Shiber	Adaptive rotary catheter for opening obstructed bodily vessels
AU2013381855B2 (en)	2013-03-09	2018-08-02	Chiesi Farmaceutici S.P.A.	Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) *	2014-01-06	2014-05-07	南京正科制药有限公司	一种坎格雷洛晶型ⅰ
MA41326A (fr)	2015-01-14	2021-04-28	Chiesi Farm Spa	Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
WO2018234565A1 (en)	2017-06-23	2018-12-27	Chiesi Farmaceutici S.P.A.	METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY
TWI857957B (zh)	2018-06-19	2024-10-11	德商Ｕｃｂ製藥有限公司	吡啶基及吡基-（氮）吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5637967B2 (cs) *	1973-05-17	1981-09-03
JPS5874966A (ja) *	1981-10-28	1983-05-06	Mikuni Jukogyo Kk	高圧往復動機の軸封装置
JPS5874696A (ja) *	1981-10-30	1983-05-06	株式会社　ヤトロン	アデノシン三リン酸の安定化方法
AU659645B2 (en) *	1991-06-26	1995-05-25	Inhale Therapeutic Systems	Storage of materials
US5563122A (en) *	1991-12-09	1996-10-08	Asahi Kasei Kogyo Kabushiki Kaisha	Stabilized parathyroid hormone composition
SK281309B6 (sk) *	1993-02-10	2001-02-12	Astra Pharmaceuticals Limited	N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov
CZ306394A3 (en) *	1993-12-14	1995-08-16	Lilly Co Eli	Aqueous solution of inclusion complex of benzothiophene derivative with water-soluble cyclodextrins, process of its preparation and a pharmaceutical composition containing thereof
DE4405426A1 (de) *	1994-02-21	1995-08-24	Boehringer Mannheim Gmbh	Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
JP2001516329A (ja) *	1995-06-07	2001-09-25	ザリージェンツオブザユニバーシティオブカリフォルニア	ポリヌクレオチド複合体の安定化
FR2740686B1 (fr) *	1995-11-03	1998-01-16	Sanofi Sa	Formulation pharmaceutique lyophilisee stable
ID21635A (id) *	1996-12-20	1999-07-08	Astra Pharma Prod	Komposisi farmasi untuk pengeringan beku

1997
- 1997-07-11 SE SE9702680A patent/SE9702680D0/xx unknown
1998
- 1998-06-19 TW TW087109890A patent/TW585764B/zh not_active IP Right Cessation
- 1998-06-29 DE DE69836023T patent/DE69836023T2/de not_active Expired - Lifetime
- 1998-06-29 NZ NZ502073A patent/NZ502073A/en not_active IP Right Cessation
- 1998-06-29 JP JP2000502063A patent/JP4950380B2/ja not_active Expired - Lifetime
- 1998-06-29 TR TR2000/00006T patent/TR200000006T2/xx unknown
- 1998-06-29 WO PCT/SE1998/001287 patent/WO1999002542A1/en not_active Ceased
- 1998-06-29 HU HU0002622A patent/HU226489B1/hu unknown
- 1998-06-29 CN CN98807089A patent/CN1263533A/zh active Pending
- 1998-06-29 ES ES98934017T patent/ES2273425T3/es not_active Expired - Lifetime
- 1998-06-29 CZ CZ20000083A patent/CZ298110B6/cs not_active IP Right Cessation
- 1998-06-29 SK SK1836-99A patent/SK285766B6/sk not_active IP Right Cessation
- 1998-06-29 PL PL337970A patent/PL192768B1/pl unknown
- 1998-06-29 EP EP98934017A patent/EP1000079B1/en not_active Expired - Lifetime
- 1998-06-29 EE EEP200000022A patent/EE04119B1/xx unknown
- 1998-06-29 SI SI9830865T patent/SI1000079T1/sl unknown
- 1998-06-29 UA UA2000010491A patent/UA65576C2/uk unknown
- 1998-06-29 KR KR1020007000205A patent/KR100786654B1/ko not_active Expired - Lifetime
- 1998-06-29 CN CNA2006100092846A patent/CN1864696A/zh active Pending
- 1998-06-29 PT PT98934017T patent/PT1000079E/pt unknown
- 1998-06-29 AT AT98934017T patent/ATE340801T1/de active
- 1998-06-29 AU AU83625/98A patent/AU8362598A/en not_active Abandoned
- 1998-06-29 DK DK98934017T patent/DK1000079T3/da active
- 1998-06-29 US US09/125,165 patent/US6130208A/en not_active Expired - Lifetime
- 1998-06-29 ID IDW20000028A patent/ID24716A/id unknown
- 1998-06-29 CA CA002295628A patent/CA2295628C/en not_active Expired - Lifetime
- 1998-06-29 RU RU2000103216/14A patent/RU2216330C2/ru active
- 1998-06-29 BR BR9810703-8A patent/BR9810703A/pt not_active Application Discontinuation
- 1998-06-29 ZA ZA985669A patent/ZA985669B/xx unknown
- 1998-06-29 IL IL13386898A patent/IL133868A0/xx unknown
- 1998-06-30 AR ARP980103182A patent/AR013157A1/es not_active Application Discontinuation
- 1998-07-10 MY MYPI98003170A patent/MY116421A/en unknown
- 1998-07-21 SA SA98190328A patent/SA98190328B1/ar unknown
1999
- 1999-12-30 IS IS5331A patent/IS2439B/is unknown
2000
- 2000-01-03 IL IL133868A patent/IL133868A/en not_active IP Right Cessation
- 2000-01-10 NO NO20000123A patent/NO329918B1/no not_active IP Right Cessation
2006
- 2006-11-27 CY CY20061101705T patent/CY1105805T1/el unknown

Also Published As

Publication number	Publication date
AR013157A1 (es)	2000-12-13
JP2001509512A (ja)	2001-07-24
PL337970A1 (en)	2000-09-11
MY116421A (en)	2004-01-31
DE69836023T2 (de)	2007-04-12
DK1000079T3 (da)	2006-11-20
WO1999002542A1 (en)	1999-01-21
SE9702680D0 (sv)	1997-07-11
CA2295628A1 (en)	1999-01-21
CZ200083A3 (cs)	2000-06-14
SK183699A3 (en)	2000-07-11
HUP0002622A3 (en)	2002-04-29
ZA985669B (en)	1999-01-11
IL133868A (en)	2010-05-17
KR100786654B1 (ko)	2007-12-21
TW585764B (en)	2004-05-01
ID24716A (id)	2000-08-03
JP4950380B2 (ja)	2012-06-13
AU8362598A (en)	1999-02-08
US6130208A (en)	2000-10-10
SK285766B6 (sk)	2007-07-06
RU2216330C2 (ru)	2003-11-20
PL192768B1 (pl)	2006-12-29
HU226489B1 (en)	2009-03-02
EP1000079B1 (en)	2006-09-27
ES2273425T3 (es)	2007-05-01
SI1000079T1 (sl)	2007-08-31
HUP0002622A2 (hu)	2001-05-28
DE69836023D1 (de)	2006-11-09
NO20000123D0 (no)	2000-01-10
BR9810703A (pt)	2000-08-08
NO20000123L (no)	2000-03-03
HK1026429A1 (en)	2000-12-15
IS5331A (is)	1999-12-30
UA65576C2 (uk)	2004-04-15
KR20010021647A (ko)	2001-03-15
ATE340801T1 (de)	2006-10-15
NZ502073A (en)	2001-09-28
CN1263533A (zh)	2000-08-16
EE04119B1 (et)	2003-08-15
TR200000006T2 (tr)	2000-07-21
EE200000022A (et)	2000-10-16
CZ298110B6 (cs)	2007-06-27
CY1105805T1 (el)	2011-02-02
PT1000079E (pt)	2006-12-29
EP1000079A1 (en)	2000-05-17
SA98190328B1 (ar)	2006-08-15
CN1864696A (zh)	2006-11-22
IS2439B (is)	2008-11-15
CA2295628C (en)	2008-07-29
IL133868A0 (en)	2001-04-30

Legal Events

Date	Code	Title	Description
2018-07-09	MK1K	Patent expired

Publication	Publication Date	Title
US6130208A (en)	2000-10-10	Formulation containing a nucleotide analogue
NO327142B1 (no)	2009-05-04	Farmasoytisk preparat som omfatter en nukleotidanalog, mannitol og et modifiserende additiv, anvendelse av nevnte preparat samt fremgangsmate for dets fremstilling
AU2003257524B2 (en)	2006-04-06	New formulation
HK1026429B (en)	2007-01-12	New formulation
MXPA00000100A (en)	2000-09-08	New formulation
CZ293470B6 (cs)	2004-05-12	Použití pencicloviru pro léčení herpes@viru@Ú u lidí a farmaceutický prostředek
MXPA99005664A (en)	2000-01-01	Pharmaceutical compositions for freeze drying
HK1026366B (en)	2003-01-10	Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying